New authorized message (important)

You are receiving this as part of your free subscription to Straight-Up Profits. To remove your email from this list, unsubscribe here.

When we see offers from other publishers that might interest you, we pass them along. Below you'll find one from our colleagues at Legacy Research. Please note that their opinions may differ from what you read in Money Morning. Dear Reader, Our customer service team in Delray Beach, Florida, has been flooded with calls and emails about the Most Important (and Urgent) Briefing of Jeff's 30-Year Career. We heard a few questions in particular keep coming up. Here are some answers... Q: No one in the news or media is talking this opportunity. I don't even get any hits on Google. What gives? A: As Jeff shares in the presentation, this is a rare situation that 99.99% of the people out there have no idea could happen. The only reason Jeff knows about it is because he saw something he wasn't supposed to see in a closed-door meeting in Cambridge. (More on this below.) This is a fast-moving situation. Jeff made it priority number one to get this message out ASAP so people would have the chance to make their move BEFORE this story makes the front page of the Wall Street Journal or is picked up by the talking heads on CNBC. Mission Accomplished! Q: I keep hearing a lot about CRISPR in the news. What makes this potential cure and this company so special? A: This company was formed by the five modern "Einsteins" who first discovered CRISPR a decade ago. Together, they've created a brand-new CRISPR treatment that's so effective... the FDA has already given this cure the "green light." And they are quietly treating patients in trials at our nation's top clinics as we speak... including Harvard's very own hospital and the Kellogg Center. What's more, a consortium of 14 of the world's savviest biotech insiders are all in on this small cap. Including the former science advisor of the world's richest man: Bill Gates. All told, they've invested over $100 million in this small cap. Look, you don't bet $100 million on a long shot. But as you'll see Jeff explain here... if you want to join these insiders, time is running out. Q: What makes Jeff so sure this is actually going to happen? A: Jeff saw something that he wasn't supposed to see at a closed-door meeting in Cambridge. Top industry officials and key tech executives were in attendance - including the chief scientific officer of this small cap. Based on what Jeff witnessed, he has a 100% conviction this small cap could unveil the greatest breakthrough of his career. Furthermore, Jeff recently got his hands on a little-known government document. It's an official record of this small cap's new CRISPR potential cure for blindness. And it MANDATES that this small cap MUST REPORT trial results. In the FDA's own words, results must "accurately and rapidly [be] reported to the agency." In other words, they must report trial results ASAP. It's a concrete fact. That's why Jeff is urging people to make their move before it's too late. Q: This sounds really interesting, but before I pull the trigger... am I covered by a guarantee? A: Yes! Actually, Jeff has issued two guarantees so you can move forward and sleep well at night with your decision. The first is a full 90-day satisfaction guarantee that lets you get a full credit if you contact our customer service team within the first 90 days. The second guarantee is something I don't think anyone has ever done in this industry before. Jeff is 100% guaranteeing this company will follow FDA mandate and make an announcement regarding their potential cure for blindness. If they don't, Jeff will give you another year of service for free. Q: What if I'm too late? A: Naturally, this is a situation we're following very closely, and we will discontinue this offer once the company makes an announcement. Simply put: If you go to this page and it's not active, you missed out. Sorry. Finally, Jeff asked me to pass along his thanks for everyone's questions and overall interest in this briefing. It's something he deeply believes in and he's grateful for your attention and support. Sincerely, Van Bryan Managing Editor, Exponential Tech Investor You are receiving this e-mail at, its028@gmail.com, as a part of your free subscription to Straight-Up Profits. Remove your email from this list: Unsubscribe To cancel by mail or for any other subscription issues, write us at: Straight-Up Profits | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://straightupprofits.com © 2020 Straight-Up Profits All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Straight-Up Profits. 1125 N Charles Street, Baltimore MD 21201.